FIGURE 5 from PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies
Year: 2023
Type: other
Abstract: PRT543 inhibits growth of PARP inhibitor–resistant ovarian and breast cancer models in vitro and in vivo. Cell proliferation of UWB1.289 parental, BRCA1-overexpressing, and olaparib-resistant cell lines was assessed by cell-titer glo assays following 10 days treatment with olaparib (A) or PRT543 (B; n = 3). C,In vivo mouse CDX of A2780 ovarian cancer cells treated with PRT543, olaparib, or in combination (n = 8 mice/group). D,In vivo mouse ovarian cancer PDX (CTG-1086, BRCA1 deletion) with acquired resistance to olaparib was treated with PRT543 or olaparib (n = 10 mice/group). E,In vivo mouse breast cancer PDX (CTG-089, BRCA1/2 hemizygous deletion) with acquired resistance to olaparib was treated with PRT543 or olaparib (n = 10 mice/group). A–E, Data are represented as mean ± SEM. C–E, Asterisks indicate statistical significance from vehicle (**, P <0.01) using a Dunnett test.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4388424263